

Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN

Almuthe Christine Hauer

Standards and Guidelines

IBD

Paediatrics

February 14, 2019

This updated position statement from 2015 onwards summarizes current evidence and provides joint consensus statements on the recommended practice of biosimilar use in children with inflammatory bowel disease.

KEY POINTS

- Biologic therapies have changed outcomes for both adult and pediatric patients with inflammatory bowel disease.
- The first biosimilar of infliximab was introduced to the pharmaceutical market in September 2013.
- Accumulated data for both adults and children demonstrate that biosimilars are an effective and safe alternative to the originator biologic.
- The document provides consensus statements on recommended practice for biosimilar use in pediatric IBD, updating a 2015 position paper by the ESPGHAN IBD Porto group.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/e64a5aaa-9360-11ed-a015-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.